55.94
0.13%
+0.07
After Hours:
55.94
LivaNova PLC stock is currently priced at $55.94, with a 24-hour trading volume of 396.57K.
It has seen a +0.13% increased in the last 24 hours and a +1.54% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $55.61 pivot point. If it approaches the $56.58 resistance level, significant changes may occur.
LivaNova PLC Stock (LIVN) Financials Data
LivaNova PLC (LIVN) Revenue 2023
LIVN reported a revenue (TTM) of $1.15 billion for the quarter ending December 31, 2023, a +12.89% rise year-over-year.
LivaNova PLC (LIVN) Net Income 2023
LIVN net income (TTM) was $17.55 million for the quarter ending December 31, 2023, a +120.34% increase year-over-year.
LivaNova PLC (LIVN) Cash Flow 2023
LIVN recorded a free cash flow (TTM) of $39.93 million for the quarter ending December 31, 2023, a -8.00% decrease year-over-year.
LivaNova PLC (LIVN) Earnings per Share 2023
LIVN earnings per share (TTM) was $0.32 for the quarter ending December 31, 2023, a +119.75% growth year-over-year.
LivaNova PLC Stock (LIVN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
KOZY WILLIAM A | Chairman and CEO |
Feb 29 '24 |
Option Exercise |
0.00 |
14,512 |
0 |
32,333 |
Saia Andrea Lynn | Director |
Dec 31 '23 |
Option Exercise |
0.00 |
1,468 |
0 |
11,113 |
Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
2,254 |
0 |
2,254 |
Shvartsburg Alex | CFO |
Dec 15 '23 |
Option Exercise |
0.00 |
613 |
0 |
9,548 |
KOZY WILLIAM A | Director |
Oct 14 '23 |
Option Exercise |
0.00 |
10,311 |
0 |
21,550 |
Story Brooke | Director |
Sep 15 '23 |
Option Exercise |
0.00 |
1,725 |
0 |
1,725 |
Hebbelinck Trui | Chief Human Resources Officer |
Sep 15 '23 |
Option Exercise |
0.00 |
440 |
0 |
7,748 |
WILVER PETER M | Director |
Jun 15 '23 |
Option Exercise |
0.00 |
2,082 |
0 |
2,082 |
SCHERMERHORN TODD C | Director |
Jun 15 '23 |
Option Exercise |
0.00 |
2,082 |
0 |
4,416 |
Shvartsburg Alex | CFO |
Jun 15 '23 |
Option Exercise |
0.00 |
1,577 |
0 |
9,677 |
LivaNova PLC Stock (LIVN) Latest News
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
Zacks Investment Research
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Benzinga
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
Toll Brothers Posts Upbeat Earnings, Joins Exelon, Garmin, Bausch + Lomb And Other Big Stocks Moving Higher On Wednesday
Benzinga
LivaNova (LIVN) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research
About LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression. The company's product portfolio also includes various strategic portfolio initiatives, such as transcatheter mitral valve replacement, an implant device for the treatment of mitral regurgitation through the replacement of native mitral valve; VITARIA to treat heart failure through VNS; and ANTHEM-HFpEF to study autonomic regulation therapy in patients experiencing symptomatic heart failure with preserved ejection fraction, as well as treatment resistant depression. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Cap:
|
Volume (24h):